Warnings Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Talk Evidence - Z drugs, subclinical hypothyroidism and Drazen's dozen
This week on the podcast, (2.02) a listener asks, when we suggest something to stop, should we suggest an alternative instead? (8.24) Helen tells us to stop putting people on treatment for subclinical hypothyroidism, but what does that mean for people who are already receiving thyroxine? (20.55) Carl has a black box warning about z drugs, and wonders what the alternative for sleep are. (30.11) Finally the NEJM has publi shed Jeff Drazen's dozen most influential papers - but not a systematic review amongst them. Cue the rant. Reading list: Rapid rec on subclinical hypothyroidism https://www.bmj.com/content/365/bmj.l20...
Source: The BMJ Podcast - June 25, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Talk Evidence - Z drugs, subclinical hypothyroidism and Drazen ’s dozen
This week on the podcast, (2.02) a listener asks, when we suggest something to stop, should we suggest an alternative instead? (8.24) Helen tells us to stop putting people on treatment for subclinical hypothyroidism, but what does that mean for people who are already receiving thyroxine? (20.55) Carl has a black box warning about z drugs, and wonders what the alternative for sleep are. (30.11) Finally the NEJM has published Jeff Drazen's dozen most influential papers - but not a systematic review amongst them. Cue the rant. Reading list: Rapid rec on subclinical hypothyroidism https://www.bmj.com/content/365/bmj.l2006...
Source: The BMJ Podcast - June 25, 2019 Category: General Medicine Authors: BMJ Group Source Type: podcasts

FDA Drug Safety Podcast: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Listen to an audio podcast of the December 19, 2017 FDA Drug Safety Communication "FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings". This is an update to the FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue, issued May 22, 2017. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

FDA Drug Safety Podcast: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease
Listen to an audio podcast of the February 22, 2018 FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease. As a result, we have added a new warning about this increased risk of death in patients with heart disease, and advised prescribers to consider using other antibiotics in such patients (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

FDA Drug Safety Podcast: FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease
Listen to an audio podcast of the February 1, 2018 FDA Drug Safety Communication warning that the liver disease medicine Ocaliva (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis, increasing the risk of serious liver injury. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

FDA Drug Safety Podcast: FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
On February 21, 2019 FDA concluded there is an increased risk of death with Uloric (active ingredient febuxostat) compared to another gout medicine, allopurinol. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 27, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate
Listen to an audio podcast of the February 2, 2017 Drug Safety Communication: FDA is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. As a result, we are requesting the manufacturers of over-the-counter (OTC) antiseptic products containing chlorhexidine gluconate to add a warning about this risk to the Drug Facts labels. Prescription chlorhexidine gluconate products already contain a warning about the possibility of serious allergic reactions in their labels. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

FDA Drug Safety Podcast: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - February 9, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts